Copyright
©The Author(s) 2017.
World J Hepatol. Sep 8, 2017; 9(25): 1064-1072
Published online Sep 8, 2017. doi: 10.4254/wjh.v9.i25.1064
Published online Sep 8, 2017. doi: 10.4254/wjh.v9.i25.1064
Table 1 Baseline patient characteristics
No. of patients | n = 392 | |
Gender (male/female) | 159/233 | |
Age, yr | 71.0 | (64.0-77.0) |
< 65 yr vs ≥ 65 yr | 99/293 | |
Laboratory data | ||
Level of viremia (log IU/mL) | 6.2 | (5.8-6.5) |
< 6.0 vs ≥ 6.0 | 137 vs 255 | (35.1% vs 64.9%) |
Platelet count (× 104/mm3) | 12.6 | (9.2-16.7) |
10 < vs ≥ 10 | 114/278 | (29.0% vs 70.4%) |
ALT (IU/L) | 41 | (29-65) |
γ-GTP(IU/L) | 34 | (22-57) |
Other data | ||
Prior treatment | ||
IFN vs PEG plus RBV vs TVR vs SMV | 70/147/13/9 | |
NS5A polymorphisms, n (%) | ||
L31 substitution, n = 288 | 10 (3.5) | |
Y93 substitution, n = 321 | 27 (8.4) | |
L31 and/or Y93, n = 321 | 35 (10.9) |
Table 2 Pretreatment and post-treatment major RAVs of 17 patients who did not achieve SVR12 (NS3:D168, NS5A:L31, and Y93 substitution)
No. | Pretreatment | Post-treatment | |||||||||
C.C. | D168 | L31 | Y93 | Other NS3 | Other NS5A | D168 | L31 | Y93 | Other NS3 | Other NS5A | |
1 | BT | E | - | - | - | - | E | - | - | - | R30H |
2 | REL | - | L/I | - | - | A92T | - | M | - | - | A92K |
3 | NR | - | - | H | V170I | Q54Y | - | I | H | V170I | Q54Y |
4 | BT | Y | - | - | - | Q54H | Y | F | H | - | Q54H |
5 | NR | E | - | - | Q80R, V170I | Q54H | E | V | H | Q80R, V170I | Q54H |
6 | BT | E | - | - | - | Q54H | E | V/M | H | V170I | Q54H |
7 | BT | - | M/L | - | - | Q54V | V | M/V | H | - | Q54V |
8 | BT | - | - | H | - | Q54H | V | M | H | - | Q54H |
9 | REL | - | - | H | - | Q62E | V | I | H | - | Q62E |
10 | BT | - | - | H/Y | - | - | T | M | H | - | - |
11 | BT | - | - | H/Y | - | - | V | V/F | H | V170I | - |
12 | BT | Y | F | H | - | - | D | F | H | - | Q54H |
13 | BT | - | - | - | - | Q54H, A92T | V | - | - | - | Q54H, A92K |
14 | REL | - | - | - | - | Q54H | E | - | - | - | P32L, Q54H, A92K |
15 | BT | - | - | - | - | Q62N | V | V | H | - | Q62N |
16 | BT | - | - | - | - | - | - | V | H | - | - |
17 | REL | - | - | - | - | - | E | M | H | - | - |
- Citation: Fujii H, Umemura A, Nishikawa T, Yamaguchi K, Moriguchi M, Nakamura H, Yasui K, Minami M, Tanaka S, Ishikawa H, Kimura H, Takami S, Nagao Y, Shima T, Itoh Y. Real-world efficacy of daclatasvir and asunaprevir with respect to resistance-associated substitutions. World J Hepatol 2017; 9(25): 1064-1072
- URL: https://www.wjgnet.com/1948-5182/full/v9/i25/1064.htm
- DOI: https://dx.doi.org/10.4254/wjh.v9.i25.1064